VitVio
Category: AI in Healthcare
A computer vision and AI platform designed to digitize the operating room by automating administrative tasks and surgical workflow documentation through ambient sensing. VitVio was founded in 2023. The company is led by Thomas Knox. Based in Boston, USA. Team size: 10-50. Total funding raised: $10M ($8M Seed + $2M earlier). Latest round: Seed ($8M, Oct 2025). Key investors include Bek Ventures, LDV Capital, Tiny Supercomputer Investment Company (TSIC), Balnord, Thornapple River Capital, Joe Mullings, Mati Staniszewski.
- Founded
- 2023
- Headquarters
- Boston, USA
- Team size
- 10-50
- Total funding
- $10M ($8M Seed + $2M earlier)
Value proposition
Reduces the administrative burden on surgical teams by automating manual data entry, improving OR throughput, and providing real-time operational insights to maximize hospital ROI.
Products and solutions
Vetro (3D-native AI platform for OR intelligence), 3D Spatial Context Engine, Autonomous surgical phase logging & op-note generation, Mission Control real-time multi-OR workflow dashboard, Instrument/tray tracking & rationalization, AI agents for periop staff orchestration & EHR write-back
Unique value
Applies 'autonomous retail' grade computer vision technology to the surgical theater, allowing for 'zero-click' data capture without requiring staff to wear sensors or interact with screens.
Target customer
Health systems, large hospitals, ambulatory surgery centers (ASCs), and surgical department administrators.
Industries served
Healthcare, HealthTech, Surgical Operations, Hospital Administration
Technology advantage
Leverages proprietary computer vision models developed by pioneers in autonomous checkout (AiFi/Standard AI) to track complex human-object interactions in high-stakes clinical environments with high precision.
How they differentiate
VitVio utilizes 'zero-click' ambient sensing technology derived from autonomous retail (computer vision) to automate administrative and operational logistics. Unlike competitors that focus primarily on surgical technique or video-based clinical coaching, VitVio focuses on the 'OR as a factory,' automating documentation and asset tracking without requiring staff interaction with screens.
Main competitors
Theator, Caresyntax, ExplORer Surgical (GHX)
Key partnerships
Royal Orthopaedic Hospital (Clinical validation partner), Bek Ventures, LDV Capital, Tiny Supercomputer Investment Company (TSIC)
Notable customers
Royal Orthopaedic Hospital
Major milestones
Relocated global headquarters to Boston, MA in 2024, Successfully completed clinical validation pilot with the Royal Orthopaedic Hospital, Closed $8M Seed funding round led by Bek Ventures in October 2025, Opened commercial access to Vetro 3D-native AI OR platform (July 2026), 2nd place Digital Health, Nebius AI Discovery Awards (July 2026)
Growth metrics
Boston HQ; Vetro commercially open (July 2026) after pilots in US/UK; live deployments and new partners in New York, LA, London NHS/private; expanding access across US, Europe, Latin America, UK, Middle East.
Market positioning
Early-stage disruptor in the Surgical Operations and HealthTech infrastructure market.
Geographic focus
United States, United Kingdom, Europe, Latin America, Middle East
Patents and IP
Proprietary IP in computer vision algorithms and ambient sensing configurations for clinical environments (specific public filings not disclosed).
About Thomas Knox
Thomas Knox is a seasoned product leader with a specialized background in scaling computer vision and AI startups. Prior to founding VitVio, he held key leadership roles at autonomous retail pioneers AiFi and Standard AI, where he oversaw the deployment of AI solutions across 150+ locations. His experience also includes scaling the travel platform Kiwi.com and serving as a member of the Forbes Technology Council.
Latest news about VitVio
More AI in Healthcare companies
Official website: https://www.vitvio.com